Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology
Authors
Keywords
-
Journal
BMC BIOTECHNOLOGY
Volume 12, Issue 1, Pages 88
Publisher
Springer Nature
Online
2012-11-21
DOI
10.1186/1472-6750-12-88
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: A gynecologic oncology group study
- (2012) Jennifer M. Rubatt et al. GYNECOLOGIC ONCOLOGY
- Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC
- (2011) L. Friboulet et al. CLINICAL CANCER RESEARCH
- Prognostic Role of ERCC1 in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
- (2011) Joshua A. Roth et al. Clinical Lung Cancer
- DNA repair gene excision repair cross complementing-group 1 (ERCC1) in head and neck squamous cell carcinoma: analysis of methylation and polymorphism (G19007A), protein expression and association with epidemiological and clinicopathological factors
- (2011) Lucianne Maia Costa Lima et al. HISTOPATHOLOGY
- Treatment-Related Protein Biomarker Expression Differs between Primary and Recurrent Ovarian Carcinomas
- (2011) D. A. Zajchowski et al. MOLECULAR CANCER THERAPEUTICS
- Role of Adjuvant Chemotherapy in NSCLC (Stages I to III)
- (2011) Melissa H. Coleman et al. Surgical Oncology Clinics of North America
- Comparative Nephrotoxicity of Cisplatin and Nedaplatin:Mechanisms and Histopathological Characteristics
- (2011) Takeki Uehara et al. Journal of Toxicologic Pathology
- Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all?
- (2010) Sandra Geiger et al. ANTI-CANCER DRUGS
- Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone
- (2010) Corinne M. Doll et al. RADIOTHERAPY AND ONCOLOGY
- Mechanisms of Cisplatin Nephrotoxicity
- (2010) Ronald P. Miller et al. Toxins
- Automated ERCC1 Immunohistochemistry in Non-small Cell Lung Cancer
- (2010) Stefanie Arbogast et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Class III -tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma
- (2009) Y. Koh et al. ANNALS OF ONCOLOGY
- Immunodetection of DNA Repair Endonuclease ERCC1-XPF in Human Tissue
- (2009) N. R. Bhagwat et al. CANCER RESEARCH
- 14-3-3ζ escorts CCTα for calcium-activated nuclear import in lung epithelia
- (2009) Marianna Agassandian et al. FASEB JOURNAL
- Tissue Profiling of the Mammalian Central Nervous System Using Human Antibody-based Proteomics
- (2009) Jan Mulder et al. MOLECULAR & CELLULAR PROTEOMICS
- Platinum Resistance: The Role of DNA Repair Pathways
- (2008) L. P. Martin et al. CLINICAL CANCER RESEARCH
- Patients with ERCC1-Negative Locally Advanced Esophageal Cancers May Benefit from Preoperative Chemoradiotherapy
- (2008) M. K. Kim et al. CLINICAL CANCER RESEARCH
- Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies
- (2008) N. Pabla et al. KIDNEY INTERNATIONAL
- Human protein factory for converting the transcriptome into an in vitro–expressed proteome
- (2008) Naoki Goshima et al. NATURE METHODS
- Transcriptional regulation of phosphatidylcholine biosynthesis
- (2008) Hiroyuki Sugimoto et al. PROGRESS IN LIPID RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now